Replies to post #599813 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

skitahoe, I agree that initial approvals to treat only nGBM and rGBM patients in the UK and the EU, can be funded with a limited approved label indications of just rGBM and nGBM only.

That would probably max out at about 2,000 to 3,000 patients per month in the UK and the EU. There would also be similar patient numbers in the US plus Canada.

But, for a tissue-agnostic approval of DCVax-L, demand would go up to 10,000 to 100,000 patients per month in the UK plus the EU, and there would be similar patient demand numbers in the US and Canada.

Then, you would have to calculate the cost to expand Flaskworks devices and DCVax manufacturing facilities to other continents and countries around the world.